|
|
2016 Featured Talks » Immuno-Oncology: Rational combination therapy
Chris Boshoff, part 1 from MCC Industry Relations on Vimeo.
Chris Boshoff, part 2 from MCC Industry Relations on Vimeo.
Chris Boshoff, MD, PhD, FMedSci
Vice President, Early Development
Translational and Immuno-Oncology
Pfizer
Chris Boshoff, M.D., Ph.D., FMedSci, is the Vice President for Early Development, Translational and Immuno-Oncology at Pfizer where he directs the strategies for early cancer drug development, and precision and immuno-oncology. He is a Co-Chair of the Oncology Research and Development Board, overseeing the early portfolio of cancer studies across the Pfizer Enterprise. Dr. Boshoff obtained his PhD from the Institute of Cancer Research in London and trained as a medical oncologist at the Royal Marsden and Royal Free Hospitals in London. Before joining Pfizer in 2013, he was the Director of the University College London (UCL) Cancer Institute (2007-2013). He has published more than 150 original articles covering cancer biology, tumor virology, and experimental cancer medicine.
|
